
1. nephron. 2018;140(4):275-281. doi: 10.1159/000493807. epub 2018 oct 25.

incidence characteristics de novo renal cryoglobulinemia after
direct-acting antivirals treatment egyptian hepatitis c cohort.

fayed a(1), el nokeety mm(2), samy abdelaziz t(2), samir hh(2), hamza wm(3), el
shabony t(2).

author information: 
(1)department internal medicine, nephrology unit, school medicine, cairo
university, cairo, egyptdr.fayed@gmail.com.
(2)department internal medicine, nephrology unit, school medicine, cairo
university, cairo, egypt.
(3)department pathology, school medicine, cairo university, cairo, egypt.

introduction: side effects profile new direct--acting antivirals for
the treatment hepatitis c virus (hcv) fully elucidated.
objective: cross-sectional study, aim describe incidence and
characteristics novel observation de novo renal cryoglobulinemic
glomerulonephritis successful treatment daa.
methodology: total 12,985 hepatitis c patients (genotype iv) received the
new daa. successful treatment, patients deranged renal functions or
proteinuria referred nephrology department assessment. the
clinical manifestations ranged lower limb edema development of
purpura skin lesions. cryoglobulins tested serum using pcr
detection.
results: fifty patients detectable de novo cryoglobulins serum. the
most common type renal biopsies membranoproliferative glomerulonephritis
(52%) chronic kidney disease (ckd) developed 46% cases.
conclusion: de novo cryoglobulinemic glomerulonephritis progression ckd
may rarely complicate successful treatment hcv using direct-acting antivirals.

Â© 2018 s. karger ag, basel.

doi: 10.1159/000493807 
pmid: 30359992  [indexed medline]

